$ATRC

WEHRWEIN SVEN sold $946K of ATRC

WEHRWEIN SVEN sold 25,000 shares of AtriCure, Inc. (ATRC) at $37.84 ($0.95M total) on 2026-07-28.

Original reporting
SEC EDGAR · WEHRWEIN SVEN
Published Jul 30, 2026, 8:57 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 8:59 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ATRC
Neutral
medium confidence
Mentioned
$ATRC
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATRCNeutralLow
01

Why it matters

The disclosed open-market sale may slightly affect sentiment, but it does not provide new guidance, trial results, contracts, or regulatory developments.

02

Market read

Traders may monitor insider activity as a sentiment input, but this filing alone is unlikely to change the fundamental outlook.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but the article provides no context on motivations or whether other insiders sold/bought around the same time.

Relevance 5/10Novelty 4/10Timing: filed 2026-07-30, transaction dated 2026-07-28

Background

The article is an SEC Form 4 insider transaction disclosure for AtriCure, Inc.

Company-level read

Ticker impact

$ATRCNeutralMedium confidence
Context

AtriCure director WEHRWEIN SVEN filed a Form 4 open-market sale of 25,000 shares at $37.84 on 2026-07-28.

Expected impact

Low likelihood of a sustained price move solely from this sale; any impact is likely short-lived and sentiment-driven.

Evidence & confidence

This is a routine insider transaction disclosure with no 10b5-1 plan and no accompanying operational or financial update in the text.

Market effects

No sector-wide implications are stated; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs, so the signal may be weak.

Key entities

  • AtriCure, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • WEHRWEIN SVEN

    Director who sold 25,000 shares in an open-market transaction.

Related articles

$ATRCHigh

AtriCure, Inc. (ATRC): Results of Operations and Financial Condition

AtriCure, Inc. (ATRC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-7232026.htm EX-99.1 Document Exhibit 99.1 For immediate release July 23, 2026 AtriCure Reports Second Quarter 2026 Financial Results • Second Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year • Second Quarter 2026 profitabi